Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen Anakinra Arthritis Advisory Committee Review Expected In August

Executive Summary

Amgen expects an advisory committee review of its rheumatoid arthritis treatment anakinra in August.

You may also be interested in...



Amgen/Praecis Ask For FDA Meeting After Plenaxis Deemed "Not Approvable"

Amgen and Praecis are requesting a meeting with FDA to discuss issues surrounding the NDA for their prostate cancer treatment Plenaxis (abarelix).

Amgen/Praecis Ask For FDA Meeting After Plenaxis Deemed "Not Approvable"

Amgen and Praecis are requesting a meeting with FDA to discuss issues surrounding the NDA for their prostate cancer treatment Plenaxis (abarelix).

Amgen IL-1ra Sepsis Data May Help Support Arthritis Launch, Firm Says

Amgen's extensive database for interleukin-1 receptor antagonist in sepsis patients may help the company position the product as a safer alternative to the TNF inhibitor Enbrel in the rheumatoid arthritis market, Amgen Senior VP-Sales & Marketing Stan Benson suggested during a Nov. 8 analysts meeting in New York City.

UsernamePublicRestriction

Register

OM008605

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel